Banji Awosika, MD
Nephrology · Ocoee, FLNPI 1295770428
Payments from drug & device makers
Across 289 payments — averaging $56.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- Fresenius USA Marketing, Inc.$1K
- AstraZeneca$961
- Amgen$765
- Travere Therapeutics, Inc.$625
- Otsuka America Pharmaceutical, Inc.$545
- plus $4K from 26 others
What the payments were for
- Consulting fees$1,06313%
- Food & beverage$6,58180%
- Education$6127%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $8,409 |
| Fresenius USA Marketing, Inc. | 21 | $1,468 |
| AstraZeneca(2 entities) | 29 | $961 |
| Amgen(2 entities) | 35 | $765 |
| Travere Therapeutics, Inc. | 26 | $625 |
| Otsuka America Pharmaceutical, Inc. | 18 | $545 |
| OPKO Pharmaceuticals, LLC | 22 | $501 |
| Vifor Pharma, Inc. | 21 | $482 |
| Aurinia Pharma U.S., Inc. | 9 | $400 |
| Calliditas Therapeutics US Inc. | 11 | $328 |
| Mallinckrodt Hospital Products Inc. | 14 | $301 |
| Novartis | 5 | $241 |
| ANI Pharmaceuticals, Inc. | 4 | $204 |
| Bayer | 5 | $128 |
| AbbVie | 8 | $125 |
| Akebia Therapeutics Inc | 6 | $122 |
| Mallinckrodt Enterprises LLC | 6 | $110 |
| Renalytix AI, Inc. | 5 | $95 |
| Lilly USA, LLC | 5 | $86 |
| Ardelyx, Inc. | 3 | $80 |
| Kyowa Kirin, Inc. | 4 | $79 |
| Shield Therapeutics Inc | 3 | $55 |
| Boehringer Ingelheim | 2 | $54 |
| Alnylam Pharmaceuticals Inc. | 2 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $46 |
| Baxter Healthcare | 2 | $43 |
| Scpharmaceuticals Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| Abbott | 1 | $19 |
| Cormedix Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,423 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 64 | $95,881 |
| VelphoroSucroferric Oxyhydroxide | 24 | $54,287 |
| AuryxiaFerric Citrate | 14 | $30,163 |
| FarxigaDapagliflozin Propanediol | 33 | $17,918 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $13,686 |
| ProcritEpoetin Alfa | 11 | $13,612 |
| EliquisApixaban | 23 | $12,271 |
| Sevelamer Carbonate | 47 | $9,244 |
| KerendiaFinerenone | 12 | $5,456 |
| Cinacalcet Hcl | 33 | $4,623 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 14 | $3,149 |
| Calcitriol | 147 | $2,299 |
| Hydralazine Hcl | 93 | $1,023 |
| Torsemide | 18 | $331 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 48 | $323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $501 | $95,88164 claims |
| Fresenius USA Marketing, Inc.Velphoro | $1,468 | $54,28724 claims |
| AstraZenecaFarxiga, Lokelma | $961 | $31,60446 claims |
| Akebia Therapeutics IncAuryxia | $122 | $30,16314 claims |
| BayerKerendia | $128 | $5,45612 claims |
| Lilly USA, LLCHumulin 70-30 | $86 | $3,14914 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $204 | $15013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.
Other nephrology in Ocoee
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.